Nativis Announces Early Data from Study in Treatment of Patients with Newly Diagnosed Glioblastoma

Thursday, November 15, 2018 Cancer News
Email Print This Page Comment bookmark
Font : A-A+

Nativis Research Partner to Present at the Society for Neuro-Oncology Annual Meeting in New Orleans, November 16

SEATTLE, Nov. 14, 2018 /PRNewswire-PRWeb/ -- Nativis, Inc., a clinical stage therapeutic device company developing

non-invasive treatments for cancers and other serious diseases, today announced further encouraging data supporting the use of ultra-low radio frequency energy (ulRFE®) in patients with newly diagnosed glioblastoma (GBM). An abstract with interim data from an ongoing clinical study will be presented by Dr. Garni Barkhoudarian of the John Wayne Cancer Institute and Pacific Neuroscience Institute at Saint John's Health Center at the 23nd Annual Meeting of the Society for Neuro-Oncology (SNO) in New Orleans, Friday, November 16. Nativis will once again support the SNO Conference at the Benefactor Sponsor Level.

The Nativis Voyager® system, an investigational, non-sterile, non-invasive, non-thermal, non-ionizing, battery-operated, portable medical device delivers a specific, localized, low level (?22kHz) magnetic field in the form of a ulRFE cognate. The cognate is generated by measuring and recording the oscillating magnetic field produced by molecules in solution and is delivered locally via an electromagnetic coil worn externally on the head of the patient. The coil is connected to a controller clipped to a pocket, belt, or arm band worn by the patient. Examples of recorded molecules that may be used are commercial drugs and chemicals, siRNA molecules to downregulate protein pathway, and endogenous compounds like hormones.

Dr. Barkoudarian's presentation concludes that the Nativis Voyager system appears to be safe for the treatment of newly diagnosed GBM; no serious device-related adverse events were reported. Additionally, the data suggest the Nativis Voyager system might have clinical utility for the treatment of GBM and warrant further study in patients with newly diagnosed GBM. The full abstract may be viewed by following this LINK.

"The Nativis Voyager technology is unique in its approach to the treatment of patients with newly diagnosed GBM," said Chris Rivera, Nativis CEO. "It is a simple device that is easy and comfortable for the patient to wear. Our work with the Nativis Voyager system has produced results that are promising, and we are planning further clinical trials to produce additional, confirmatory data."

"The encouraging data from this and other studies demonstrate that a ulRFE cognate can be used to knock down specific key pathways associated with cancer signaling," Rivera added. "Our novel technology has the potential to transform the way we treat cancer. With these encouraging data in hand, we will continue to develop the Nativis Voyager system for the treatment of GBM with the aim to expand to additional indications in the future." Nativis has an additional clinical study ongoing for recurrent GBM in the US and Australia (http://www.clinicaltrials.gov).

Rivera ended the list of the company's SNO Conference activities by announcing that Mike Butters, co-founder of Nativis, will present on Thursday, November 15th. The presentation entitled, "Nativis Voyager®: A disruptive approach to cancer treatment", will describe the principles underlying the operation of Nativis' device, the effects of the Voyager in biological systems and clinical trials for the treatment of glioblastoma.

About Nativis, Inc.

Founded in 2002 and headquartered in Seattle, WA, Nativis is a clinical-stage, therapeutic device company. Nativis has invented and patented a groundbreaking technology that utilizes precisely targeted, ultra-low radio frequency energy (ulRFE) to specifically regulate metabolic pathways on the molecular and genetic levels – without chemicals, radiation or drugs – delivered via a simple-to-use non-invasive device called Nativis Voyager. The company's goal is to transform disease treatment on a global scale with ulRFE that can potentially be applied to a wide range of medical conditions, as well as to veterinary medicine and non-medical applications). Nativis' initial focus is on the treatment of patients with brain cancer, who are not well served by conventional standard of care therapies, which often results in poor outcomes and devastating side effects. Additional pre-clinical work is focused on exploring new applications in oncology and pain management. The Nativis Voyager® system is an investigational medical device, limited by United States law to investigational use only.

Media Relations Contact: Dennis Kroft dkroft@nativis.com 201-602-8354

 

SOURCE Nativis



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store